Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient populat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2024-10, Vol.17 (1), p.102-10, Article 102
Main Authors: Iacoboni, Gloria, Navarro, Víctor, Sesques, Pierre, Rejeski, Kai, Bastos-Oreiro, Mariana, Serpenti, Fabio, Martin Lopez, Ana Africa, Iraola-Truchuelo, Josu, Delgado, Javier, Perez, Ariadna, Guerreiro, Manuel, Caballero, Ana Carolina, Martinez-Cibrian, Nuria, Luzardo Henriquez, Hugo, Sanchez Pina, Jose Maria, Sancho, Juan-Manuel, Ghesquieres, Hervé, Mussetti, Alberto, Lopez Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda, Anna, Bosch, Francesc, Martin Garcia-Sancho, Alejandro, Kwon, Mi, Subklewe, Marion, Kuhnl, Andrea, Bachy, Emmanuel, Barba, Pere, Villacampa, Guillermo, Abrisqueta, Pau
Format: Article
Language:English
Subjects:
Adult
Aged
CAR-T
Care and treatment
Cohort Studies
Development and progression
Disease Progression
Female
Hemoglobin
Humans
Immunotherapy, Adoptive - methods
Large B-cell lymphoma
Life Sciences
Lymphoma, Large B-Cell, Diffuse - therapy
Male
Middle Aged
Non-Hodgkin's lymphomas
Overall survival
Prognosis
Score
T cells
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient population is lacking. A training cohort of 216 patients with progressive disease (PD) after CAR-T from 12 Spanish centers was used to develop the Post-CAR Prognostic Index (PC-PI); primary endpoint was overall survival (OS) from CAR-T progression. Validation was performed in an external cohort from three different European centers (n = 204). The prognostic score incorporated five variables, assessed at time of PD to CAR-T: ECOG (> 0), hemoglobin ( 1) and time from CAR-T to PD (
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-024-01608-8